Skip to content

Tranlational Research: A Phase I study of Oxyfedrine and Sulfasalazine in Patients with Solid Tumor

Tranlational Research: A Phase I study of Oxyfedrine and Sulfasalazine in Patients with Solid Tumor - FC001-TR Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-jRCT1030230529
Enrollment
54
Registered
2023-12-22
Start date
2023-12-22
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

unresectable recurrent solid tumor

Interventions

None listed

Sponsors

Shitara Kohei
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Willing to participate in the "XXXX". 2) Written consent has been obtained from the patient for this ancillary study. 3) Age 18 years or older on the date consent is obtained.

Exclusion criteria

Exclusion criteria: 1) Patients who are regarded as inappropriate for enrollment by investigators.

Design outcomes

Primary

MeasureTime frame
Correlation of objective response rate or disease control rate with biomarkers

Secondary

MeasureTime frame
Progression-free survival, duration of response, duration of treatment success, correlation of biomarkers with overall survival, etc.

Contacts

Public ContactHiromichi Nakajima

National Cancer Center Hospital East

fc001-p1_core@east.ncc.go.jp+81-4-7133-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026